Integration of an automated insulin delivery system with a one-year continuous glucose monitoring system by Sequel Med Tech and Senseonics
The wait is over for people with type 1 diabetes seeking advanced diabetes management solutions. The Twiist Automated Insulin Delivery (AID) System, developed by Sequel Med Tech, has officially integrated with Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system. This integrated system is now available in the U.S. starting from July 7, 2025, with a prescription for individuals aged 6 and above.
The Twiist AID system, launched in July 2025, utilizes the Tidepool Loop algorithm and features a unique, circular, tubed insulin pump with sound-wave-based insulin measurement for precise dosing and quicker occlusion detection. The system allows customizable blood sugar targets as low as 87 mg/dL and includes intelligent meal absorption profiles, predictive blood sugar forecasting, and flexible insulin delivery controls via the pump button, iPhone app, or Apple Watch.
The integration of Twiist with Eversense 365 CGM offers greater personalization, more choice, and the potential for improved outcomes for people living with diabetes. This collaboration aims to enhance diabetes management, offering people with diabetes more tools for care, potentially leading to improved glucose control, increased convenience, and greater flexibility.
Sequel CEO and Co-Founder Alan Lotvin stated that the company is committed to investing in innovations that empower people with diabetes with options in managing their diabetes. Senseonics President and CEO Tim Goodnow shared similar sentiments, stating that the collaboration will provide people with diabetes the most recent innovations in advanced pump, algorithm, and sensor technologies.
This integration marks a significant step forward in the joint commitment of Sequel and Senseonics to simplify diabetes management and improve quality of life for people with diabetes. The companies are united by a shared commitment to advance diabetes technology and expand partnerships to give people with diabetes more choice and flexibility in managing their diabetes.
[1] Twiist AID System Launch [2] Twiist AID System Details [3] Senseonics Eversense 365 CGM FDA Clearance [4] Twiist AID System Prescription Information
- The launch of the Twiist Automated Insulin Delivery (AID) System in July 2025 brings a promising solution for people with type 2 diabetes who seek advanced diabetes management, featuring sound-wave-based insulin measurement and intelligent meal absorption profiles.
- The Twiist AID System, integrated with Senseonics' Eversense 365 Continuous Glucose Monitoring (CGM) system, offers customizable blood sugar targets, predictive blood sugar forecasting, and flexible insulin delivery controls, aiming to provide greater personalization and improved outcomes for those managing medical-conditions such as chronic diseases like type-2 diabetes.
- With FDA clearance already obtained by Senseonics for their Eversense 365 CGM system, the collaboration between Sequel Med Tech and Senseonics aims to expand health-and-wellness options for people with diabetes, focusing on nutrition and quality of life, by investing in research and development of innovations in diabetes management technologies.
